99 Tc-Methylene Diphosphonate Treatment is Safe and Efficacious for Osteoporosis in Postmenopausal Differentiated Thyroid Cancer Patients Undergoing TSH Suppression: A Three-Center Non-Randomized Clinical Study

To investigate the effects of Tc-methylene diphosphonate ( Tc-MDP) on osteoporosis (OS) in postmenopausal patients with differentiated thyroid cancer (DTC) under thyroid stimulating hormone (TSH) suppression. Patients (n = 142) were divided into two groups: (1) Tc-MDP (n = 70) and (2) alendronate (n...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2022, Vol.14, p.995
Main Authors: Xie, Jianhao, Yuan, XueYu, Mao, Weiqing, Cai, Haidong, Gao, Kejia, Lv, Zhongwei, Wang, Hui, Ma, Chao
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the effects of Tc-methylene diphosphonate ( Tc-MDP) on osteoporosis (OS) in postmenopausal patients with differentiated thyroid cancer (DTC) under thyroid stimulating hormone (TSH) suppression. Patients (n = 142) were divided into two groups: (1) Tc-MDP (n = 70) and (2) alendronate (n = 72) treatments (NCT02304757). Bone mineral density (BMD) in the lumbar spine and hip was evaluated by DXA, along with bone turnover markers, safety, and quality of life (QOL) using SF-36 at three time points: before treatment and at 6 and/or 12 months after treatment. The percentage change of BMD in total lumbar spine or hip showed no significant difference throughout the study (P > 0.025). Tc-MDP and alendronate treatment alone significantly increased BMD in the lumbar spine, but alendronate treatment also significantly increased BMD in total hip at 6 and 12 months, as compared with the baseline. There were no significant differences in the results of the SF-36 scores between the two treatment groups at any time during the whole study period. Tc-MDP significantly increased bone formation markers of osteocalcin at 6 and 12 months (P all < 0.05), PINP at 12 months (P = 0.001), and bone resorption markers of β-CTX at 6 and 12 months (p < 0.05) as compared with the alendronate treated group. No adverse event was observed in the Tc-MDP treatment group compared with alendronate (P = 0.014). Tc-MDP was as efficacious as alendronate in the improvement of lumbar BMD for DTC patients with OS under TSH stimulation. Tc-MDP was shown to be safe and improved patients' QOL.
ISSN:1179-1322
1179-1322